Given the undeniable role of PGRN in the clinical course of GBM, the combined evaluation of PGRN expression level along with typical GBM-associated biomarkers (e.g., IDH mutations, 1p19q deletion or MGMT promoter methylation) could probably provide strong prognostic factors in predicting the clinical outcomes of this tumour type. This evidence concerns the gene GRN and neoplasm.